# Layer-wise Relevance Propagation

Clinical survival models usually emit distribution parameters, abstract quantities that do not map onto the risk factors clinicians recognize. ODDS-DR reparameterizes the network outputs so they add up in log-odds, letting each output neuron be attributed directly to input features. On the SUPPORT2 and aortic coarctation cohorts its discrimination matches or exceeds DeepSurv, DeepHit and DSM, with a C-index of 0.83 for the log-logistic variant on SUPPORT2.

Clinical survival models usually emit distribution parameters, abstract quantities that do not map onto the risk factors clinicians recognize. ODDS-DR reparameterizes the network outputs so they add up in log-odds, letting each output neuron be attributed directly to input features. On the SUPPORT2 and aortic coarctation cohorts its discrimination matches or exceeds DeepSurv, DeepHit and DSM, with a C-index of 0.83 for the log-logistic variant on SUPPORT2.

DeepDelivery treats the human proteome as a candidate pool for mRNA delivery scaffolds: deep learning models trained on viral capsid proteins, filtered by a dual-model screen, nominated 512 candidates from 109,375 human sequences. Of 15 candidates tested experimentally, 12 formed mRNA-encapsulating particles and mediated functional delivery; RTL8B reached 73.2% transduction in HEK293T reporter cells, above the reference proteins Arc (56.5%), PEG10 (53.1%) and PNMA2 (67.4%). The results support human proteins as a source of modularly engineerable delivery scaffolds, while immunogenicity and in vivo behavior remain untested.

DeepDelivery treats the human proteome as a candidate pool for mRNA delivery scaffolds: deep learning models trained on viral capsid proteins, filtered by a dual-model screen, nominated 512 candidates from 109,375 human sequences. Of 15 candidates tested experimentally, 12 formed mRNA-encapsulating particles and mediated functional delivery; RTL8B reached 73.2% transduction in HEK293T reporter cells, above the reference proteins Arc (56.5%), PEG10 (53.1%) and PNMA2 (67.4%). The results support human proteins as a source of modularly engineerable delivery scaffolds, while immunogenicity and in vivo behavior remain untested.